One of the USA’s largest compounders, Hims & Hers, has announced the acquisition of a peptide facility in California.

Spanish dermatology company Almirall was trading 4% higher on Monday afternoon after presenting its full-year 2024 financial ...

Mitsubishi Tanabe Pharma (MTPC) today announced that the European Medicines Agency (EMA) has accepted for review the ...

Swiss generics and biosimilars major Sandoz has announced the launch of Pyzchiva (ustekinumab-ttwe) in the USA. From today, ...

Earlier this month, the Norwegian government launched the cancer strategy Joint Efforts Against Cancer, with five national ...

The US Food and Drug Administration (FDA) late Friday revealed it has approved Ctexli (chenodiol) for the treatment of ...

Japanese drug major Shionogi announced that Jeil Pharmaceutical, its partner in South Korea, has obtained marketing approval ...

US antivirals giant Gilead Sciences recently announced that the US Food and Drug Administration (FDA) has accepted its New ...

Last week’s significant news was dominated by licensing deals and mergers and acquisitions. US biotech giant Biogen entered ...

French drug major Sanofi and the US unit of Israel’s Teva Pharmaceutical Industries have presented new, detailed results from the RELIEVE UCCD Phase IIb study of duvakitug, a human IgG1-λ2 monoclonal ...

The US Food and Drug Administration (FDA) said it has determined the shortage of semaglutide injection products, a glucagon-like peptide 1 (GLP-1) medication, is now resolved.

Once the hottest property in biotech, gene therapy company bluebird bio has been sold for less than $500 million after a long series of setbacks.